To verify the pluripotency of healthy control iPSCs (201B7 and Nips-B2) and NPC patient-derived iPSCs (NPC5–1 and NPC6–1), we evaluated the expression levels of OCT4, NANOG, SOX2, KLF4, and MYC genes, i.e., a set of pluripotent markers, via RT-PCR. This evidence concerns the gene NANOG and nasopharyngeal carcinoma.